Develops drugs for diseases where the immune system attacks the body.
No change
Greenlight owns 93,520 shares of Immunovant, worth about $4 million. That’s less than $1 of every $100 they have in stocks. They didn’t really buy or sell any between April and June.
Mar 31
93,520
Jun 30
93,520
The numbers
Shares they own
93,520
Value on Jun 30, 2026
$3,603,325
about $4 million
Share of their money
0.1%
less than $1 of every $100 · 43rd of 46
Price per share on Jun 30
$38.53
Kind
Shares
Also owned by
No other fund we follow
More about Immunovant ›
The value uses the price on Jun 30, 2026. The fund may have paid a different price.